

Nucleus RadioPharma Announces Strategic Alliance with Thermo Fisher Scientific to Advance Radiopharmaceutical Development and Clinical Execution

Agreement supports Pharma and Biotech innovators bringing radiopharmaceutical therapies to patients more efficiently

Rochester, MN, June 15, 2026 — [Nucleus RadioPharma Inc.](#), today announced a strategic alliance with [Thermo Fisher Scientific](#) to help pharma and biotech companies accelerate radiopharmaceutical programs from development through clinical execution.

The two companies bring together complementary expertise to help innovators address key challenges in the development and delivery of radiopharmaceutical therapies – an emerging class of targeted medicines requiring specialized development, manufacturing, clinical and regulatory capabilities – through a more coordinated path to patients.

*“Radiopharmaceuticals have the potential to transform care for patients with serious diseases, and developing and delivering these therapies requires highly specialized expertise, infrastructure, and coordination,” said **Stephen Hahn, M.D., Chief Executive Officer of Nucleus RadioPharma.***

“Working with Thermo Fisher, we aim to simplify access to critical development and clinical capabilities, with the shared goal of helping innovators deliver important new therapies to patients faster.”

For Thermo Fisher’s PPD™ clinical research business, this agreement reflects a continued commitment to excellence in oncology and hematology clinical development. With deep oncology expertise, high-precision clinical trial execution, and specialized radiopharmaceutical capabilities, Thermo Fisher aims to help customers advance differentiated therapies for patients with cancer and other serious diseases.

*“Thermo Fisher is committed to helping customers advance medicines that can make a meaningful difference for patients,” said **Mike Shafer, Executive Vice President and President, Biopharma Services, Thermo Fisher.** “Through this collaboration with Nucleus RadioPharma, we are bringing together scientific expertise, patient-centered trial execution and operational discipline to help radiopharmaceutical innovators navigate the complexity of developing and delivering these therapies.”*



The arrangement is initially focused on the United States, with potential to expand into other regions based on customer needs and operational capabilities. Customer choice remains central to the collaboration, with each company continuing to operate independently.

About Nucleus RadioPharma

Nucleus RadioPharma is an innovative CDMO dedicated to the development and manufacturing of targeted radiotherapies. With an emphasis on innovation and quality, Nucleus provides services spanning formulation and analytical development, regulatory documentation, and drug product manufacturing. Its technology platforms are at the forefront of radiopharmaceutical research, designed to advance new therapies through clinical trials to commercialization. Learn more at <https://nucleusrad.com/>.

For more information, please contact:

Nucleus RadioPharma

or

Chad Crookshanks

BD@nucleusrad.com

Sr. Director, Marketing and Communications

ccrookshanks@nucleusrad.com